当前位置:
首页
网刊
药物临床试验中疗效指标的选择
药物临床试验中疗效指标的选择
刘炳林

国家食品药品监督管理总局药品审评中心,北京 100038
Selection of endpoints for efficacy in clinical trials of new drugs
(Center for Drug Evaluation,China Food and Drug Administration,Beijing 100038,China)

摘要参考文献相关文章

起始页:2113

摘要:[摘要] 本文参考国内外药品注册相关法规、技术要求和指导原则,根据20多年新药审评经验和对技术标准及指导原则的深入理解,对新药临床试验中疗效指标概念和与疗效指标选择密切相关的几种疗效指标类型进行了分析和说明。对药物临床试验中主要疗效指标的特点以及主要疗效指标和次要疗效指标选择的基本原则进行了梳理和归纳。对疗效指标选择时需要考虑的问题进行了详细的概括和总结。对使用几种常见类型疗效指标进行疗效评价时需要注意的事项和问题进行了认真的分析和讨论。

关键词:[关键词] 新药;临床试验;疗效指标;疗效指标的选择;主要疗效指标;考虑的问题

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] Referring to domestic and international drug registration regulations, technical standards and guidelines,this paper analyzes and explains the concepts and types of efficacy endpoints related to selection for endpoints in clinical trial for drugs based on twenty years of experience in drug evaluation and in-depth understanding of technical standards and guidelines of new drug registration. The characteristics of the primary efficacy endpoints and the basic principles of selecting the primary and second endpoints for efficacy in clinical trials for drugs are also discussed and summarized. The problems that need to be considered when selecting the endpoints for efficacy in the clinical trials are explained. This paper illustrates the matters needing attention and problems in the use of several common types of endpoints in clinical trials.

Key words:[Key words] new drugs;clinical trials;endpoints of efficacy; selection of endpoint;primary endpoint;issues to consider

    [1] FDA. Code Federal Regultation,title21, Part314.126;Adequate and well-controlled studies[EB/OL].[2017-02-28].http://www.ecfr.gov/cgi-bin/text-idx?SID=c7a0186dc459c77acd757 b066f8c2f38&mc=true&node=se21.5.314_1126&rgn=div8.
    [2] 国家食品药品监督管理总局. 中药新药临床研究一般原则[EB/OL].(2015-11).http://www.sda.gov.cn/WS01/CL1616/134582.html.
    [3] ICH-E9. Statistical Principles for Clinical Trials[EB/OL].

    [1998-02-05].http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
    [4] 刘炳林. 药物临床试验中疗效评价指标及常见评价方法[J].中国新药杂志,2016,25(18):2074-2077.
    [5] 刘炳林. 药物临床试验中有效性指标的分类[J].中国新药杂志,2016,25(10):1103-1107.
    [6] 国家食品药品监督管理总局.《药物临床试验的生物统计学指导原则》[EB/OL].(2016-06).http://www.sda.gov.cn/WS01/CL0087/154780.html.
    [7] 精神药物新药临床评价研究技术平台专家组.精神药物临床试验技术指导原则[M]. 第一册.上海:上海科技教育出版社,2012:27-28.
    [8] ICH-E10. Choice of Control Group in Clinical Trials[EB/OL].

    [2000-07-20].http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
    [9] ICH-E8. General Considerations for Clinical Trials[EB/OL].

    [1997-07-17].http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/general-considerations-for-clinical-trials.html?.
    [10] 国家食品药品监督管理总局.药物临床试验的一般考虑指导原则[EB/OL].(2017-01).http://www.sda.gov.cn/WS01/CL0087/168752.html.
    [11] 周贤忠,刘仁沛,中国药学会药物临床评价研究专业委员会组织翻译. 临床试验的设计与分析——概念与方法学[M].北京:北京大学医学出版社,2010:468-469.
    [12] FDA. Good Review Practice:Clinical Review of Investigational New Drug Applications(MaPP)[EB/OL].

    [2013-12-02].http://www.fda.gov/downloads/drugs/guidance complianceregulatory information/ucm377108.pdf.
    [13] FDA.Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics[EB/OL].

    [2007-05].https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071590.pdf.
    [14] 刘炳林.中药新药治疗卒中临床试验中关键技术要点考虑[J].中国新药杂志,2015,24(10):1105-1107.
    [15] 胡大一.重视中间终点的评估,关注亚临床动脉粥样硬化的预防干预[J].中国医刊,2004,39(10):62-63.
    [16] 科学技术部.2016年《国家重点支持的高新技术领域》(生物与新药医药)[EB/OL].

    [2016-02-24].http://c.360webcache.com/c?m=eb949de5b9c0e508b16bad9b1c667c9f&q=&u=http%3A%2F%2Fwww.jiyunet.cn%2Fjs-zixun%2Fzixun02.htm.
    [17] ANDREW S, LEVEY MD. Proteinuria as a surrogate outcome in CKD: report of a scientificworkshop sponsored by the national kidney foundation and the US food and drug Administration[J]. Am J Kidney Dis, 2009,54(2): 205-226.
    [18] FDA.Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims[EB/OL].

    [2009-12].https://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm 193282.pdf.
    [19] 刘炳林,薛斐然. 药物临床价值评估的主要考虑因素及问题

    [J].中国新药杂志,2017,26(5):504-508.